A psma inhibitor, compound and use
By optimizing the core structure and functional group design of PSMA inhibitors, the problems of insufficient affinity and stability of existing inhibitors have been solved, enabling efficient diagnosis and treatment of prostate cancer and other PSMA-expressing tumors, and improving the accuracy and safety of diagnosis and treatment.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE)
- Filing Date
- 2019-02-03
- Publication Date
- 2026-07-24
AI Technical Summary
Existing PSMA inhibitors have shortcomings in affinity and structural stability, resulting in poor efficacy in the diagnosis and treatment of prostate cancer, especially in intermediate- and high-risk patients and patients with advanced disease, making it difficult to achieve high-sensitivity and high-specificity imaging monitoring and targeted therapy.
A novel PSMA inhibitor core structure was developed. By optimizing the compound's structural design, its affinity for PSMA was improved and its stability was enhanced. It can be combined with different functional groups for diagnosis and treatment, including optical imaging, radionuclide imaging and radiotherapy.
This invention achieves a PSMA inhibitor with a low Ki value, improving the accuracy and safety of diagnosis and treatment. It is applicable to a variety of tumors or cells that express PSMA, including prostate cancer, lung cancer, and kidney cancer, and has broad application prospects.
Smart Images
Figure CN111138397B_ABST